Adenovirus vectors and complement system

腺病毒载体和补体系统

基本信息

  • 批准号:
    7192472
  • 负责人:
  • 金额:
    $ 25.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-03-05 至 2008-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ongoing studies make it clear that the intravenous injection of high doses of Adenovirus (Ad) based vectors offer a tremendous potential for treatment of disseminated cancers, inherited diseases, vascular diseases, as well for gene therapy of the liver for a variety of hepatic/genetic diseases. However, the systemic administration of Ad based vectors is currently viewed as a highly risky maneuver, as significant acute toxicities can be incurred, including chemokine/cytokine release, endothelial cell damage, Kupffer cell activation, hypotension, thrombocytopenia (low platelet counts), and as noted in the Gelsinger tragedy, the systemic inflammatory response syndrome and death. Precious little is known about the innate systems that are immediately triggered by injection of an Ad vector at high doses. Activation of these systems is predicted to be pivotal in initiating and/or modulating subsequent host immune responses, both innate and adaptive. One of these first line innate host defense systems is the complement system. Inappropriate complement activation can result in a number of dire consequences, including anaphylactoid reactions, ARDS (adult respiratory distress syndrome), hypotensive shock, DIC (disseminated intravascular coagulation), cytokine release and systemic inflammatory response syndromes. More specifically, complement activation products released after complement activation (i.e: C3a, C5a) are potent inflammatory mediators, which are known to activate Kupffer cells, as well activate vascular endothelium, leading to neutrophil recruitment, and platelet aggregation. Intriguingly, many of these consequences are also noted after high dose Ad injections. Based upon these considerations, we forward the following Central Hypothesis: "Ad vector interactions with the complement system results in many of the limitations and toxicities typically attributed to the use of Ad vectors". The aims of this proposal will directly test the central hypothesis. The results of this line of investigation will move the field of gene transfer using systemically administered Ad vectors forward.
描述(由申请人提供):正在进行的研究清楚地表明,静脉注射高剂量腺病毒(Ad)载体为治疗播散性癌症、遗传性疾病、血管疾病以及各种肝脏/遗传疾病的肝脏基因治疗提供了巨大的潜力。然而,基于Ad载体的全身给药目前被认为是一种高风险的操作,因为可能会产生显著的急性毒性,包括趋化因子/细胞因子释放、内皮细胞损伤、库普弗细胞活化、低血压、血小板减少(血小板计数低),以及如Gelsinger悲剧中所述的全身炎症反应综合征和死亡。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.
通过在治疗性癌症疫苗接种中加入重组艾美耳球虫抗原,增强了肿瘤抗原的免疫识别。
  • DOI:
    10.1007/s00262-015-1659-7
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Quiroga,Dionisia;Aldhamen,YasserA;Appledorn,DanielM;Godbehere,Sarah;Amalfitano,Andrea
  • 通讯作者:
    Amalfitano,Andrea
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrea na Amalfitano其他文献

Andrea na Amalfitano的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrea na Amalfitano', 18)}}的其他基金

ER-Localized Aminopeptidases in Ankylosing Spondylitis
强直性脊柱炎中的内质网定位氨肽酶
  • 批准号:
    8670551
  • 财政年份:
    2010
  • 资助金额:
    $ 25.06万
  • 项目类别:
ER-localized aminopeptidases in ankylosing spondylitis
强直性脊柱炎中内质网定位的氨肽酶
  • 批准号:
    8476986
  • 财政年份:
    2010
  • 资助金额:
    $ 25.06万
  • 项目类别:
ER-localized aminopeptidases in ankylosing spondylitis
强直性脊柱炎中内质网定位的氨肽酶
  • 批准号:
    8110051
  • 财政年份:
    2010
  • 资助金额:
    $ 25.06万
  • 项目类别:
ER-localized aminopeptidases in ankylosing spondylitis
强直性脊柱炎中内质网定位的氨肽酶
  • 批准号:
    8284209
  • 财政年份:
    2010
  • 资助金额:
    $ 25.06万
  • 项目类别:
ER-localized aminopeptidases in ankylosing spondylitis
强直性脊柱炎中内质网定位的氨肽酶
  • 批准号:
    7983691
  • 财政年份:
    2010
  • 资助金额:
    $ 25.06万
  • 项目类别:
Adenovirus vectors and complement system
腺病毒载体和补体系统
  • 批准号:
    6861181
  • 财政年份:
    2005
  • 资助金额:
    $ 25.06万
  • 项目类别:
Adenovirus vectors and complement system
腺病毒载体和补体系统
  • 批准号:
    7147257
  • 财政年份:
    2005
  • 资助金额:
    $ 25.06万
  • 项目类别:
Adenovirus vectors and complement system
腺病毒载体和补体系统
  • 批准号:
    7178508
  • 财政年份:
    2005
  • 资助金额:
    $ 25.06万
  • 项目类别:
Adoptive Immunotherapy with Recombinant Adenvirus Vector
重组腺病毒载体的过继免疫治疗
  • 批准号:
    6989595
  • 财政年份:
    2004
  • 资助金额:
    $ 25.06万
  • 项目类别:
MODIFIED ADENOVIRUS VECTORS FOR USE IN GENE THERAPY
用于基因治疗的修饰腺病毒载体
  • 批准号:
    2906074
  • 财政年份:
    1998
  • 资助金额:
    $ 25.06万
  • 项目类别:

相似海外基金

Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
  • 批准号:
    19K09482
  • 财政年份:
    2019
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
  • 批准号:
    2273599
  • 财政年份:
    2019
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
  • 批准号:
    18K14964
  • 财政年份:
    2018
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
  • 批准号:
    16K18873
  • 财政年份:
    2016
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
  • 批准号:
    9193681
  • 财政年份:
    2016
  • 资助金额:
    $ 25.06万
  • 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
  • 批准号:
    15K18939
  • 财政年份:
    2015
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
  • 批准号:
    26450450
  • 财政年份:
    2014
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
  • 批准号:
    26893253
  • 财政年份:
    2014
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
  • 批准号:
    26462183
  • 财政年份:
    2014
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
  • 批准号:
    24701021
  • 财政年份:
    2012
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了